Ehave Company Information
|Headquarters||277 Lakeshore Rd E Suite 203,|
Oakville, ON L6J 6J3. Canada
Ehave Inc is a Canadian-based company that was incorporated in 2011. The brand seeks to develop state-of-the-art software-based technologies that facilitate the management, assessment, and correction of the rampant mental conditions affecting millions of children and young adults.
The company’s initial focus was on ADHD (Attention-deficit hyperactivity disorder), a condition characterized by elevated levels of activity, impulsive tendencies, inability to stay still for long periods, and limited focus/concentration window.
Mental health is a global crisis, and Ehave seeks to approach it using technological advancements and science. The company has an informatics platform that focuses on mental health dubbed ‘Ehave Connect.’ The platform performs the following functions:
- Offers solutions to issues regarding the management and communication with the platform’s users
- Guides assessments and interventions
- Interprets data
Under the MegaTeam brand, Ehave Inc has launched ADHD applications, focusing on embedding rehabilitation tasks and cognitive assessments, all within the confines of an attention-grabbing video game environment. These applications are available on PCs, Android, Mac, and iOS systems.
One in five Americans does not seek help for their mental health issues. This could be due to any of the following reasons:
- The financial barrier to mental healthcare
- Mental health education and awareness
- The social stigma of mental health conditions
Ehave seeks to break these barriers by providing affordable and technologically advanced therapeutic platforms to treat mental conditions.
Ehave’s CureDash acquisition
In 2020, Ehave acquired CureDash, a Californian-based company that delivers intravenous IVs to a patient’s house. Ketamine therapy is provided under the care of highly trained doctors and nurses.
CureDash was integrated into Ehave, and the company took their frontend and backend IP. CureDash was transformed into KetaDash and operates under the same principle of making household delivery of ketamine treatment to patients.
These patients are prescribed ketamine by a physician and, for one reason or another, are unable to go to the clinic to receive their intravenous doses. Ketamine is used in the treatment and management of mental conditions and pain.
On the 26th of February, Ehave announced plans to launch open testing of the ketamine IV therapy in the Q2 using progressive vein technology. KetaDash is expected to be available soon on Google Play Store and the App Store.
What does the future hold for Ehave’s MegaTeam products?
Recently, the FDA approved a video game designed as a treatment for kids with ADHD, aged eight to twelve years. The Akili video games’ approval paves the way for Ehave to accelerate its production and testing process to seek FDA approval for its MegaTeam products.